Survival following screening and preemptive antifungal therapy for subclinical cryptococcal disease in advanced HIV infection.

Objectives: Our study's primary objective was to compare 1-year survival rates between serum cryptococcal antigen (sCrAg)-positive and sCrAg-negative HIV-positive individuals with CD4+ cell counts less than 100 cells/μl without symptoms of meningitis in Zimbabwe.

Design: This was a prospective cohort study.

Methods: Participants were enrolled as either sCrAg-positive or sCrAg-negative and followed up for 52 weeks or less, with death as the outcome.